Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?Zacks Investment Research • 07/14/25
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3Business Wire • 07/07/25
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell BiologyBusiness Wire • 06/17/25
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to TradeZacks Investment Research • 06/04/25
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the USBusiness Wire • 06/03/25
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal CancerBusiness Wire • 05/30/25
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain StockZacks Investment Research • 05/19/25
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025Business Wire • 05/15/25
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development OfficerBusiness Wire • 05/12/25
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/29/25
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRBusiness Wire • 04/28/25
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment InnovationBusiness Wire • 03/19/25